Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

“Most lip fillers are hyaluronic acid, which can be dissolved with an enzyme known as hyaluronidase,” says board-certified plastic and reconstructive surgeon, Jimmy C. Sung, MD. “The ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration ...

“Most lip fillers are hyaluronic acid, which can be dissolved with an enzyme known as hyaluronidase,” says board-certified plastic and reconstructive surgeon, Jimmy C. Sung, MD. “The ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech), a twice-yearly subcutaneous injection, for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

and Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20. "We are delighted that Tecentriq Hybreza has been approved in the U.S. for all approved adult indications of the IV ...

Halozyme announces US FDA approval of Roche's Tecentriq Hybreza with Enhanze for multiple types of cancer: San Diego Saturday, September 14, 2024, 12:00 Hrs [IST] Halozyme Therape ...